AXL’s involvement in immunological evasion and resistance to immune checkpoint blockade, mediated through regulation of the tumor microenvironment (TME), presents another significant challenge, as the survival advantage conferred by these therapies is limited to a small percentage of patients.117 Therefore, it is essential to delineate the mechanistic role of AXL signaling within different populations of stromal cells to better understand TME-induced antitumor defenses. This evidence concerns the gene AXL and neoplasm.